Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

NCT05735080 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Breast Cancer Metastatic
Hormone Receptor Positive Tumor
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Ovarian Cancer
CCNE1 Amplification
Solid Tumor
Advanced Cancer
Metastatic Cancer

Interventions

DRUG: INX-315
DRUG: Fulvestrant
DRUG: Abemaciclib

Sponsor

Incyclix Bio